Arterial media calcification or pathological deposition of calcium-phosphate crystals in the vessel wall contributes significantly to the high mortality rate observed in patients with CKD. Extracellular nucleotides (ie, ATP or UTP) regulate the arterial calcification process by interacting with (1) purinergic receptors and (2) breakdown via ecto-nucleotidases, such as ectonucleotide pyrophosphatase/phosphodiesterase NPP1 or NPP3, affecting the local levels of calcification inhibitor, pyrophosphate, and stimulator inorganic phosphate (PPi/Pi ratio). Also, it has been shown that ATP analogs (ie, β,γ-methylene-ATP [β,γ-meATP]) inhibit vascular smooth muscle cell calcification in vitro. In the first experiment, daily dosing of β,γ-meATP (2 mg/kg) was investigated in rats fed a warfarin diet to trigger the development of non–CKD-related arterial medial calcifications. This study showed that β,γ-meATP significantly lowered the calcium scores in the aorta and peripheral vessels in warfarin-exposed rats. In a second experiment, daily dosing of 4 mg/kg β,γ-meATP and its metabolite medronic acid (MDP) was analyzed in rats fed an adenine diet to promote the development of CKD-related arterial medial calcification. Administration of β,γ-meATP and MDP did not significantly decrease aortic calcification scores in this model. Moreover, both compounds induced deleterious effects on physiological bone mineralization, causing an imminent risk for worsening the already compromised bone status in CKD. Due to this, it was not possible to raise the dosage of both compounds to tackle CKD-related arterial calcification. Again, this points out the difficult task of targeting solely ectopic calcifications without negatively affecting physiological bone mineralization. On the other hand, aortic mRNA expression of Enpp1 and Enpp3 was significantly and positively associated with aortic calcification scores, suggesting that normalizing the aortic NPP1/3 activity to control values might be a possible target to treat (CKD-induced) arterial media calcifications. The deposition of calcium-phosphate crystals in the arteries, also called arterial calcification, has a serious impact on the mortality in patients with chronic renal failure. We have investigated the therapeutic efficiency and safety of the drug β,γ-meATP on arterial calcification in rats. In a first experiment, rats were exposed to high, toxic dosages of warfarin, an anticoagulant, to induce arterial calcification without affecting the kidney function. The drug β,γ-meATP was able to prevent the development of mild arterial calcifications in rats exposed to warfarin. In a second experiment, rats were fed an adenine diet to trigger chronic renal failure, which leads to the development of severe arterial calcifications. Unfortunately, the drug β,γ-meATP and its metabolite medronic acid did not significantly reduce the presence of severe arterial calcifications in rats with chronic renal failure. Moreover, these compounds induced side-effects at the level of the bones, causing an imminent risk for worsening the already compromised bone status in chronic renal failure. Due to this, it was not possible to raise the dosage of both compounds to tackle arterial calcification in a chronic kidney failure setting. Again, this points out the difficult task of targeting solely arterial calcifications without negatively affecting physiological bone mineralization.